Editorial: Global Excellence in Nuclear Medicine: North America

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2023 Nov 13

PMID 37954553

Authors

Abhishek Jha

Ali Cahid Civelek

Affiliations

Soon will be listed here.

References

Jambor I, Kuisma A, Kahkonen E, Kemppainen J, Merisaari H, Eskola O . Prospective evaluation of F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial). Eur J Nucl Med Mol Imaging. 2017; 45(3):355-364. DOI: 10.1007/s00259-017-3875-1. View

Civelek A, Niglio S, Malayeri A, Lin J, Gurram S, Chalfin H . Clinical value of FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer. Urol Oncol. 2021; 39(11):787.e17-787.e21. PMC: 10211471. DOI: 10.1016/j.urolonc.2021.04.024. View

Beiderwellen K, Grueneisen J, Ruhlmann V, Buderath P, Aktas B, Heusch P . [(18)F]FDG PET/MRI vs. PET/CT for whole-body staging in patients with recurrent malignancies of the female pelvis: initial results. Eur J Nucl Med Mol Imaging. 2014; 42(1):56-65. DOI: 10.1007/s00259-014-2902-8. View

Marner L, Nysom K, Sehested A, Borgwardt L, Mathiasen R, Henriksen O . Early Postoperative F-FET PET/MRI for Pediatric Brain and Spinal Cord Tumors. J Nucl Med. 2019; 60(8):1053-1058. DOI: 10.2967/jnumed.118.220293. View

Hirsch F, Sattler B, Sorge I, Kurch L, Viehweger A, Ritter L . PET/MR in children. Initial clinical experience in paediatric oncology using an integrated PET/MR scanner. Pediatr Radiol. 2013; 43(7):860-75. PMC: 3691480. DOI: 10.1007/s00247-012-2570-4. View

Hope T, Hernandez Pampaloni M, Nakakura E, VanBrocklin H, Slater J, Jivan S . Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor. Abdom Imaging. 2015; 40(6):1432-40. DOI: 10.1007/s00261-015-0409-9. View

Freitag M, Radtke J, Afshar-Oromieh A, Roethke M, Hadaschik B, Gleave M . Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. Eur J Nucl Med Mol Imaging. 2016; 44(5):776-787. DOI: 10.1007/s00259-016-3594-z. View

Reiner C, Stolzmann P, Husmann L, Burger I, Hullner M, Schaefer N . Protocol requirements and diagnostic value of PET/MR imaging for liver metastasis detection. Eur J Nucl Med Mol Imaging. 2013; 41(4):649-58. DOI: 10.1007/s00259-013-2654-x. View

Varoquaux A, Rager O, Poncet A, Delattre B, Ratib O, Becker C . Detection and quantification of focal uptake in head and neck tumours: (18)F-FDG PET/MR versus PET/CT. Eur J Nucl Med Mol Imaging. 2013; 41(3):462-75. PMC: 3913851. DOI: 10.1007/s00259-013-2580-y. View

10.

Burns R, Mule S, Blanc-Durand P, Tofighi M, Belhadj K, Zerbib P . Optimization of whole-body 2-[F]FDG-PET/MRI imaging protocol for the initial staging of patients with myeloma. Eur Radiol. 2021; 32(5):3085-3096. DOI: 10.1007/s00330-021-08388-6. View

11.

Quick H . Integrated PET/MR. J Magn Reson Imaging. 2013; 39(2):243-58. DOI: 10.1002/jmri.24523. View

12.

Hong S, Choi S, Kim K, Park S, Kim S, Lee S . Diagnostic performance of [F]FDG-PET/MRI for liver metastasis in patients with primary malignancy: a systematic review and meta-analysis. Eur Radiol. 2019; 29(7):3553-3563. DOI: 10.1007/s00330-018-5909-x. View

13.

Grueneisen J, Schaarschmidt B, Heubner M, Aktas B, Kinner S, Forsting M . Integrated PET/MRI for whole-body staging of patients with primary cervical cancer: preliminary results. Eur J Nucl Med Mol Imaging. 2015; 42(12):1814-24. DOI: 10.1007/s00259-015-3131-5. View

14.

Veit-Haibach P, Ahlstrom H, Boellaard R, Delgado Bolton R, Hesse S, Hope T . International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncology. Eur J Nucl Med Mol Imaging. 2023; 50(12):3513-3537. PMC: 10547645. DOI: 10.1007/s00259-023-06406-x. View

15.

Taneja S, Jena A, Goel R, Sarin R, Kaul S . Simultaneous whole-body ¹⁸F-FDG PET-MRI in primary staging of breast cancer: a pilot study. Eur J Radiol. 2014; 83(12):2231-2239. DOI: 10.1016/j.ejrad.2014.09.008. View

16.

Tian M, Civelek A, Carrio I, Watanabe Y, Kang K, Murakami K . International consensus on the use of tau PET imaging agent F-flortaucipir in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2022; 49(3):895-904. PMC: 8803772. DOI: 10.1007/s00259-021-05673-w. View

17.

Queiroz M, Kubik-Huch R, Hauser N, Freiwald-Chilla B, von Schulthess G, Froehlich J . PET/MRI and PET/CT in advanced gynaecological tumours: initial experience and comparison. Eur Radiol. 2015; 25(8):2222-30. DOI: 10.1007/s00330-015-3657-8. View

18.

Cardoso F, Costa A, Norton L, Senkus E, Aapro M, Andre F . ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast. 2014; 23(5):489-502. DOI: 10.1016/j.breast.2014.08.009. View

19.

Chan S, Yeh C, Yen T, Ng S, Chang J, Lin C . Clinical utility of simultaneous whole-body F-FDG PET/MRI as a single-step imaging modality in the staging of primary nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2018; 45(8):1297-1308. DOI: 10.1007/s00259-018-3986-3. View

20.

Tian M, Watanabe Y, Kang K, Murakami K, Chiti A, Carrio I . International consensus on the use of [F]-FDG PET/CT in pediatric patients affected by epilepsy. Eur J Nucl Med Mol Imaging. 2021; 48(12):3827-3834. DOI: 10.1007/s00259-021-05524-8. View